Toxicity and adherence to treatment for latent tuberculosis infection in patients with hematologic malignancies

Infection

Volumn 41, Issue 5, 2013, Pages 903-907

  Sanchez Garcia E M ^a   Gamallo, R ^a   Blanco Moure, A ^a   Viejo, M A ^a   Amador, L ^c   Anibarro, L ^a,b  

^a Prog Gallego Prevencion y Contr TB   (Spain)

^b Hospital Meixoeiro Edificio Anexo   (Spain)

^c Servicio de Hematología   (Spain)

Author keywords

Adherence; Drug toxicity; Hematologic neoplasms; Latent tuberculosis; Tuberculosis

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ISONIAZID;

ADULT; ANTIMICROBIAL THERAPY; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; LATENT TUBERCULOSIS; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NEUROTOXICITY; PATIENT ATTITUDE; PATIENT COMPLIANCE; RISK ASSESSMENT; SIDE EFFECT; SKIN TOXICITY; TREATMENT DURATION; TUBERCULOSIS;

AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; ANTITUBERCULAR AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LATENT TUBERCULOSIS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84885187226     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-013-0489-9     Document Type: Article

References (23)

1. Stefan DC, Kruis AL, Schaaf HS, Wessels G. Tuberculosis in oncology patients. Ann Trop Paediatr. 2008;28:111-6.
2. Kaplan MH, Armstrong D, Rosen P. Tuberculosis complicating neoplastic disease. A review of 201 cases. Cancer. 1974;33:850-8.
3. Wu CY, Hu HY, Pu CY, et al. Aerodigestive tract, lung and haematological cancers are risk factors for tuberculosis: an 8-year population-based study. Int J Tuberc Lung Dis. 2011;15:125-30.
4. Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006;42:1592-5.
5. Chen CY, Sheng WH, Cheng A, et al. Clinical characteristics and outcomes of Mycobacterium tuberculosis disease in adult patients with hematological malignancies. BMC Infect Dis. 2011;11:324.
6. Silva FA, Matos JO, de Q Mello FC, Nucci M. Risk factors for and attributable mortality from tuberculosis in patients with hematologic malignances. Haematologica. 2005;90:1110-5.
7. Falagas ME, Kouranos VD, Athanassa Z, Kopterides P. Tuberculosis and malignancy. QJM. 2010;103:461-87.
8. De La Rosa GR, Jacobson KL, Rolston KV, Raad II, Kontoyiannis DP, Safdar A. Mycobacterium tuberculosis at a comprehensive cancer centre: active disease in patients with underlying malignancy during 1990-2000. Clin Microbiol Infect. 2004;10:749-52.
9. Jasmer RM, Nahid P, Hopewell PC. Clinical practice. Latent tuberculosis infection. N Engl J Med. 2002;347:1860-6.
10. González-Martín J, García-García JM, Anibarro L, et al. Consensus document on the diagnosis, treatment and prevention of tuberculosis. Enferm Infecc Microbiol Clin. 2010;28:297.e1-20.
11. Carvalho AC, Schumacher RF, Bigoni S, et al. Contact investigation based on serial interferon-gamma release assays (IGRA) in children from the hematology-oncology ward after exposure to a patient with pulmonary tuberculosis. Infection. 2013 (Epub ahead of print). doi: 10.1007/s15010-013- 0450-y.
12. [No authors listed]. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep. 2000;49:1-51.
13. Treatment for latent tuberculosis infection. Core curriculum on tuberculosis: what the clinician should know. Centers for Disease Control and Prevention. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Division of Tuberculosis Elimination. 2011. p. 109-37. http://www.cdc.gov/tb/education/corecurr/pdf/chapter5.pdf
14. Migliori GB, Zellweger JP, Abubakar I, et al. European union standards for tuberculosis care. Eur Respir J. 2012;39:807-19.
15. Anibarro L, Casas S, Paz-Esquete J, et al. Treatment completion in latent tuberculosis infection at specialist tuberculosis units in Spain. Int J Tuberc Lung Dis. 2010;14:701-7.
16. Cardona PJ. A dynamic reinfection hypothesis of latent tuberculosis infection. Infection. 2009;37:80-6.
17. Libshitz HI, Pannu HK, Elting LS, Cooksley CD. Tuberculosis in cancer patients: an update. J Thorac Imaging. 1997;12:41-6.
18. Chen CY, Sheng WH, Lai CC, et al. Mycobacterial infections in adult patients with hematological malignancy. Eur J Clin Microbiol Infect Dis. 2012;31:1059-66.
19. Pizzo PA. Fever in immunocompromised patients. N Engl J Med. 1999;341:893-900.
20. Sterling TR, Villarino ME, Borisov AS, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155-66.
21. Kwara A, Herold JS, Machan JT, Carter EJ. Factors associated with failure to complete isoniazid treatment for latent tuberculosis infection in Rhode Island. Chest. 2008;133:862-8.
22. Kunst H, Khan KS. Age-related risk of hepatotoxicity in the treatment of latent tuberculosis infection: a systematic review. Int J Tuberc Lung Dis. 2010;14:1374-81.
23. Santín Cerezales M, Benítez JD. Diagnosis of tuberculosis infection using interferon-gamma-based assays. Enferm Infecc Microbiol Clin. 2011;29:26-33.